28th Feb 2007 07:01
Henderson Morley PLC28 February 2007 28 FEBRUARY 2007 HENDERSON MORLEY PLC (AIM:HML) KOI CARP VACCINE UPDATE The Board of Henderson Morley plc ("Henderson Morley" or "the Company"), the AIMlisted drug discovery company, is pleased to provide the market and itsshareholders with an update in respect of the studies relating to the Koi Carpvaccine following the announcement made on 3 October 2006. These studies were designed to establish if the vaccine candidate is able toboost the immune system of vaccinated fish and included dose ranging studies todetermine at what dose the vaccine should be administered. A successful vaccineshould enable Koi exposed to virus, to mount a successful immune responseagainst KHV and thus prevent disease. These studies examined antibody responsesto vaccination also known as antigenicity studies. The antigenicity studies of the Koi herpes vaccine candidate have now beencompleted. The data has been analysed and the Board is pleased to announce that100% of the vaccine recipients tested have produced a significant immuneresponse. This level of immunity is a very good indicator of a successful vaccine beingdeveloped. Further field studies are ongoing and the Company will keepshareholders informed of progress in due course. ---ENDS--- ENQUIRIES: HENDERSON MORLEY PLC 0121 442 4600Andrew Knight, Chairman BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350Maxine BarnesNick Rome BREWIN DOLPHIN SECURITIES LTD 0113 241 0126Neil Baldwin Notes to Editors: Henderson Morley was founded in 1996 with the objective of developing its anti-viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platformand has been developed in-house and Henderson Morley wholly owns the patent IPR. Further information on Henderson Morley plc can be accessed through theCompany's website at www.henderson-morley.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
HML.L